FAM172A

Across TCGA pan-cancer cohorts, FAM172A RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of FAM172A’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where FAM172A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FAM172A is over-expressed in tumor, although a few such as UCEC and BLCA show the opposite, repressed pattern.

LIHC, UCEC, and BLCA are the cancer types where FAM172A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FAM172A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.771	<.001	9	view →
UCEC	All	All	−1.191	<.001	8	view →
BLCA	Male	IV	−1.177	<.001	8	view →
THCA	Male	All	−0.544	<.001	8	view →
KICH	Male	All	−1.351	<.001	7	view →
BRCA	Female	All	−0.531	<.001	6	view →
CHOL	Male	All	+1.693	<.001	5	view →
KIRP	Male	All	−0.735	<.001	4	view →
LUAD	Female	III,IV	−0.532	.028	2	view →
KIRC	All	All	+0.191	.030	2	view →
READ	All	III,IV	−0.165	.015	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

FAM172A–LIHC

Open the LIHC breakdown →